SCHEMBL29447672

SCHEMBL29447672

O=C(O)[C@H]1CCCCN1C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ RAB9A P51151 1/20 0.47
▸ FABP5 Q01469 3/20 0.46
▸ FABP7 O15540 2/20 0.46
▸ ITGB3 P05106 1/20 0.43
▸ ITGB1 P05556 1/20 0.43
▸ ITGAV P06756 1/20 0.43
▸ ITGA5 P08648 1/20 0.43
▸ ITGA4 P13612 1/20 0.43
▸ LTA4H P09960 3/20 0.42
▸ CTSB P07858 1/20 0.42
▸ CTSS P25774 1/20 0.42
▸ CTSK P43235 1/20 0.42
▸ PREP P48147 2/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ FKBP1A P62942 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119867 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL4575275 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL29402209 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL29383097 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL119365 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL30510359 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL17359219 0.99 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL30792899 0.99 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL27028706 0.99 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7
SCHEMBL119560 0.96 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2RAB9AFABP5FABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090699-A1 FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2025-03-20 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2022-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors STAT3, JAK2, STAT5A ALDH1A1 1312/4885SMN1; SMN2 3129/4885RAB9A 2697/4885
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885
US-20250090699-A1 FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF FAP, FIBP, FGF23 ALDH1A1 3542/4885SMN1; SMN2 2279/4885RAB9A 649/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS ALDH1A1 4861/4885SMN1; SMN2 4745/4885RAB9A 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback